Valutazione economica dell’incremento della copertura vaccinale contro la pertosse in Toscana: una nota preliminare

  • Paolo Bonanni
  • P. Beutels
  • A. Bechini
  • M. Maci

Economic evaluation of increased vaccination coverage against pertussis in Tuscany: a preliminary study


Objective: To validate a previously performed cost-benefit analysis of acellular pertussis vaccination with data collected ‘on the field’ in Tuscany.

Design: Empirical economic analysis based on the collection of epidemiological and economic data from different databases and medical sources in Tuscany. Incremental health and economic outcomes were calculated for each year relative to the previous one, from 1994 to 1999. Comparisons were also made between years of low (1994–96) versus high (1997–99) vaccination coverage against pertussis.

Setting: Tuscany Region, an Italian area with a population of about 3.5 million, and a vaccination coverage against pertussis of about 95% in 1999.

Main outcome measures and results: Analysis of data from Tuscany substantially confirmed the important savings (a direct net saving of € 31 and a total net saving of € 41 per additional vaccinee) associated with increased pertussis vaccination coverage that had been forecasted by the model. With the exception of the years 1995 and 1998 (when expenditure raised sharply due to a much higher vaccine consumption), all other years showed economic benefits associated with increased vaccination coverage. More importantly, vaccination is expected to show its full benefits in the next few years.

Conclusions: Considering the trend towards recommended-only vaccinations in Italy, the costs of campaigns aimed at informing and educating the Italian population about the benefits of immunisation are well worth being sustained also from an economic point of view. As shown by our study, high vaccination coverage against pertussis appears to be associated with remarkable savings.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    The Italian Vaccine Coverage Survey Working Group. Childhood vaccination coverage in Italy: results of a seven-region survey. Bull WHO 1994; 72: 885–95Google Scholar
  2. 2.
    Ministero della Sanità. Circolare 6 giugno 1995, n. 13: Esecuzione delle vaccinazioni obbligatorie e facoltative in attuazione del Piano Sanitario Nazionale 1994–96Google Scholar
  3. 3.
    Beutels P, Bonnani P, Tormans G, et al. An economic evaluation of universal pertussis vaccination in Italy. Vaccine 1999; 17: 2400–9PubMedCrossRefGoogle Scholar
  4. 4.
    Salmaso S, Gabutti G, Rota MC, et al. Pattern of susceptibility to measles in Italy. Bull WHO 2000: 78(8): 950–5PubMedGoogle Scholar
  5. 5.
    Edmunds WJ, Gay NJ, Kretzschmar M, et al. The pre-vaccination epidemiology of measles, mumps and rubella in Europe: implications for modelling studies. Epidemiol Infect 2000; 125: 635–50PubMedCrossRefGoogle Scholar
  6. 6.
    Binkin NJ, Salmaso S, Tozzi AE, et al. Epidemiology of pertussis in a developed country with low vaccination coverage: the Italian experience. Pediatr Infect Dis J 1992; 11: 653–61PubMedGoogle Scholar
  7. 7.
    Farizo KM, Cochi SL, Zell ER, et al. Epidemiological features of pertussis in the United States, 1980–1989. Clin Infect Dis 1992; 14: 708–19PubMedCrossRefGoogle Scholar
  8. 8.
    Biagini R, Bonaccorsi G, Isola A, et al. Due casi di tetano nel territorio della Valdinievole: come e perché possono ancora verificarsi episodi di una malattia di classe prima evitabile mediante intervento vaccinale. Atti della Sezione Toscana della SItI — Seduta Scientifica 15/11/1996, 1997: 55–62Google Scholar
  9. 9.
    Aoyama T, Hagiwara S, Gonda T, et al. Adverse reactions and antibody responses to acellular pertussis vaccine. J Pediatr 1986; 109: 925–30PubMedCrossRefGoogle Scholar
  10. 10.
    Aoyama T, Murase Y, Goto A, et al. Type-specific efficacy of acellular pertussis vaccine. Am J Dis Child 1988; 142: 40–2PubMedGoogle Scholar
  11. 11.
    Blackwelder WC, Storsaeter J, Cherry JD, et al. Acellular pertussis vaccines, efficacy and evaluation of clinical case definitions. Am J Dis Child 1991; 145: 1285–9PubMedGoogle Scholar
  12. 12.
    Blumberg DA, Mink CM. Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. J Pediatr 1991; 1: 119–94Google Scholar
  13. 13.
    Cody CL, Baraff LJ. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 1981; 68: 650–60PubMedGoogle Scholar
  14. 14.
    Englund JA, Edwards K, MacDonald PD. Multicenter study of acellular (AC) and whole-cell (WC) pertussis vaccines in young children. Program and abstracts 1991; 10Google Scholar
  15. 15.
    Feldman S, Perry CS, Andrew M, et al. Comparison of acellular (B type) and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines as the first booster immunization in 15- to 24-month-old children. J Pediatr 1992; 121: 857–61PubMedCrossRefGoogle Scholar
  16. 16.
    Fulginiti VA, Henderson RH. How safe are pertussis and rubella vaccines? A commentary on the Institute of Medicine Report. Pediatrics 1992; 89: 334–6PubMedGoogle Scholar
  17. 17.
    Glode M, Joffe L. Safety and immunogenicity of acellular pertussis vaccine combined with diphtheria and tetanus toxoids in 17-to 24-month-old children. Pediatr Infect Dis J 1992; 11: 530–5PubMedCrossRefGoogle Scholar
  18. 18.
    Isomura S. Efficacy and safety of acellular pertussis vaccine in Aichi Prefecture, Japan. Pediatr Infect Dis J 1988; 7: 258–62PubMedGoogle Scholar
  19. 19.
    Just M, Kanra G, Bogaerts H, et al. Two trials of an acellular DTP vaccine in comparison with a whole-cell DTP vaccine in infants: evaluation of two PT doses and two vaccination schedules. Dev Biol Stand 1991; 73: 275–83PubMedGoogle Scholar
  20. 20.
    Kamiya H, Ritsue N, Ceyhan M, et al. Immunogenicity and reactogenicity of Takeda acellular pertussis-component diphtheria-tetanus-pertussis vaccine in 2- and 3-month old children in Japan. Am J Dis Child 1992; 146: 1141–7PubMedGoogle Scholar
  21. 21.
    Kanra G, Ruuskanen O, Burnie JP. 69 kDa in acellular DTP vaccine: safety in adults and booster in 18-month old children. Program and abstracts 1991; 109Google Scholar
  22. 22.
    Long SS, Deforest A. Longitudinal study of adverse reactions following diphtheria-tetanus-pertussis vaccine in infancy. Pediatrics 1990; 85: 294–302PubMedGoogle Scholar
  23. 23.
    Mortimer EA Jr, Kimura M, Cherry JD. Protective efficacy of the Takeda acellular pertussis vaccine combined with diphtheria and tetanus toxoids following household exposure of Japanese children. Am J Dis Child 1990; 144: 899–904PubMedGoogle Scholar
  24. 24.
    Pichichero ME, Francis AB, Blatter MM, et al. Acellular pertussis vaccination of 2-month-old infants in the United States. Pediatrics 1992; 89: 882–7PubMedGoogle Scholar
  25. 25.
    Podda A, Carapella De Luca E. Acellular pertussis vaccine composed of genetically inactivated pertussis toxin: safety and immunogenicity in 12- to 24- and 2- to 4-month-old children. J Pediatr 1992; 120: 680–5PubMedCrossRefGoogle Scholar
  26. 26.
    Rothstein E, Bernstein H, Kimura M. Comparison of a 3-component acellular pertussis vaccine (DTwp) in 4–6 year old children. An annual meeting of the American Society for Microbiology 1992: 305Google Scholar
  27. 27.
    Schmitt HJ, Muller F, Zell ER, et al. Safety and immunogenicity of bicomponent and tricomponent acellular pertussis DTP vaccines in infants. Program and Abstracts 1992; 14: 275Google Scholar
  28. 28.
    Consiglio Nazionale Economia e Lavoro (CNEL). La retribuzione dei lavoratori dipendenti italiani. Fogli di informazione (CGIL), 1990.Google Scholar
  29. 29.
    Lucioni C, Ciriminna S, Di Carlo P, et al. Il costo sociale del morbillo in età pediatrica: l’epidemia a Palermo nel 1996–97. PharmacoEconomics — Italian Research Articles 1999; 1: 17–33Google Scholar
  30. 30.
    Edmunds WJ, Brisson M, Melegaro A, Gay NJ. The potential cost-effectiveness of acellular pertussis booster vaccination in England and Wales. Vaccine 2002; 20: 1316–30PubMedCrossRefGoogle Scholar
  31. 31.
    Bonanni P, Bergamini M. Factors influencing vaccine uptake in Italy. Vaccine 2002; 20: S8–S12CrossRefGoogle Scholar

Copyright information

© Adis International Limited 2003

Authors and Affiliations

  • Paolo Bonanni
    • 1
  • P. Beutels
    • 2
  • A. Bechini
    • 1
  • M. Maci
    • 1
  1. 1.Dipartimento di Sanità Pubblica, Sezione di IgieneUniversità degli Studi di FirenzeFirenzeItalia
  2. 2.Centro per la Valutazione delle Vaccinazioni, Dipartimento di Medicina SocialeUniversità degli Studi di AnversaBelgioItalia

Personalised recommendations